# First US Bancshares, Inc.: financial statements, quarterly

FUSB · Nasdaq · CIK 717806 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fusb.md) · [Financials](/companies/fusb/financials.md) · [Filings](/companies/fusb/filings.md) · [Insiders](/companies/fusb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fusb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [302](/filings/0000950170-24-123874.md) | [328 d](/filings/0000950170-25-039251.md) | [299](/filings/0000950170-25-066717.md) | [298](/filings/0000950170-25-104822.md) | [312](/filings/0001193125-25-268881.md) | [323 d](/filings/0001193125-26-103635.md) | [288](/filings/0001193125-26-211192.md) | [278](/filings/0001193125-26-337583.md) | [289](/filings/0001193125-25-268881.md) | [285 d](/filings/0001193125-26-103635.md) | [283](/filings/0001193125-26-211192.md) | [277](/filings/0001193125-26-337583.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $k | [4,419](/filings/0000950170-25-039251.md) | [4,835](/filings/0000950170-25-039251.md) | [5,237](/filings/0001193125-26-103635.md) | [5,370](/filings/0001193125-26-103635.md) | [5,832](/filings/0001193125-26-103635.md) | [5,672](/filings/0001193125-26-103635.md) | [5,121](/filings/0001193125-26-211192.md) | [5,378](/filings/0001193125-26-337583.md) | [5,619](/filings/0001193125-26-103635.md) | [5,839](/filings/0001193125-26-103635.md) | [5,725](/filings/0001193125-26-211192.md) | [5,157](/filings/0001193125-26-337583.md) |
| Income tax | $k | [704](/filings/0000950170-25-039251.md) | [782](/filings/0000950170-25-039251.md) | [651](/filings/0001193125-26-103635.md) | [612](/filings/0001193125-26-103635.md) | [722](/filings/0001193125-26-103635.md) | [599](/filings/0001193125-26-103635.md) | [554](/filings/0001193125-26-211192.md) | [9.0](/filings/0001193125-26-337583.md) | [583](/filings/0001193125-26-103635.md) | [798](/filings/0001193125-26-103635.md) | [515](/filings/0001193125-26-211192.md) | [483](/filings/0001193125-26-337583.md) |
| Net income | $k | [2,113](/filings/0000950170-24-123874.md) | [2,277](/filings/0000950170-25-039251.md) | [2,107](/filings/0000950170-25-066717.md) | [2,127](/filings/0000950170-25-104822.md) | [2,222](/filings/0001193125-25-268881.md) | [1,714](/filings/0001193125-26-103635.md) | [1,772](/filings/0001193125-26-211192.md) | [155](/filings/0001193125-26-337583.md) | [1,936](/filings/0001193125-25-268881.md) | [2,129](/filings/0001193125-26-103635.md) | [1,945](/filings/0001193125-26-211192.md) | [1,753](/filings/0001193125-26-337583.md) |
| Diluted EPS | $ per share | [0.33](/filings/0000950170-25-039251.md) | [0.36](/filings/0000950170-25-039251.md) | [0.34](/filings/0001193125-26-103635.md) | [0.34](/filings/0001193125-26-103635.md) | [0.36](/filings/0001193125-26-103635.md) | [0.29](/filings/0001193125-26-103635.md) | [0.29](/filings/0001193125-26-211192.md) | [0.03](/filings/0001193125-26-337583.md) | [0.32](/filings/0001193125-26-103635.md) | [0.36](/filings/0001193125-26-103635.md) | [0.33](/filings/0001193125-26-211192.md) | [0.31](/filings/0001193125-26-337583.md) |
| Basic EPS | $ per share | [0.35](/filings/0000950170-25-039251.md) | [0.38](/filings/0000950170-25-039251.md) | [0.36](/filings/0001193125-26-103635.md) | [0.36](/filings/0001193125-26-103635.md) | [0.38](/filings/0001193125-26-103635.md) | [0.30](/filings/0001193125-26-103635.md) | [0.30](/filings/0001193125-26-211192.md) | [0.03](/filings/0001193125-26-337583.md) | [0.33](/filings/0001193125-26-103635.md) | [0.37](/filings/0001193125-26-103635.md) | [0.34](/filings/0001193125-26-211192.md) | [0.31](/filings/0001193125-26-337583.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: not reported
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [66.1](/filings/0000950170-23-060942.md) | [50.3](/filings/0000950170-25-039251.md) | [60.2](/filings/0000950170-24-057688.md) | [58.2](/filings/0000950170-24-094495.md) | [82.3](/filings/0000950170-24-123874.md) | [47.2](/filings/0001193125-26-103635.md) | [56.0](/filings/0000950170-25-066717.md) | [54.0](/filings/0000950170-25-104822.md) | [54.7](/filings/0001193125-25-268881.md) | [73.5](/filings/0001193125-26-337583.md) | [66.6](/filings/0001193125-26-211192.md) | [58.9](/filings/0001193125-26-337583.md) |
| Total assets | $m | [1,065](/filings/0000950170-23-060942.md) | [1,073](/filings/0000950170-25-039251.md) | [1,071](/filings/0000950170-24-057688.md) | [1,083](/filings/0000950170-24-094495.md) | [1,100](/filings/0000950170-24-123874.md) | [1,101](/filings/0001193125-26-103635.md) | [1,127](/filings/0000950170-25-066717.md) | [1,143](/filings/0000950170-25-104822.md) | [1,147](/filings/0001193125-25-268881.md) | [1,155](/filings/0001193125-26-337583.md) | [1,165](/filings/0001193125-26-211192.md) | [1,148](/filings/0001193125-26-337583.md) |
| Total liabilities | $m | [978](/filings/0000950170-23-060942.md) | [982](/filings/0000950170-25-039251.md) | [978](/filings/0000950170-24-057688.md) | [989](/filings/0000950170-24-094495.md) | [1,002](/filings/0000950170-24-123874.md) | [1,002](/filings/0001193125-26-103635.md) | [1,026](/filings/0000950170-25-066717.md) | [1,041](/filings/0000950170-25-104822.md) | [1,043](/filings/0001193125-25-268881.md) | [1,049](/filings/0001193125-26-337583.md) | [1,061](/filings/0001193125-26-211192.md) | [1,043](/filings/0001193125-26-337583.md) |
| Long-term debt | $m | [10.8](/filings/0000950170-23-060942.md) | [10.8](/filings/0000950170-25-039251.md) | [10.8](/filings/0000950170-24-057688.md) | [10.8](/filings/0000950170-24-094495.md) | [10.9](/filings/0000950170-24-123874.md) | [10.9](/filings/0001193125-26-103635.md) | [10.9](/filings/0000950170-25-066717.md) | [10.9](/filings/0000950170-25-104822.md) | [10.9](/filings/0001193125-25-268881.md) | [10.9](/filings/0001193125-26-337583.md) | [11.0](/filings/0001193125-26-211192.md) | [11.0](/filings/0001193125-26-337583.md) |
| Short-term borrowings | $m | [30.0](/filings/0000950170-23-060942.md) | [10.0](/filings/0000950170-25-039251.md) | [15.0](/filings/0000950170-24-057688.md) | [15.0](/filings/0000950170-24-094495.md) | not reported | [10.0](/filings/0001193125-26-103635.md) | [45.0](/filings/0000950170-25-066717.md) | [35.0](/filings/0000950170-25-104822.md) | [20.0](/filings/0001193125-25-268881.md) | [0.0](/filings/0001193125-26-103635.md) | not reported | [25.0](/filings/0001193125-26-337583.md) |
| Shareholders' equity | $m | [87.4](/filings/0000950170-24-123874.md) | [90.6](/filings/0001193125-26-103635.md) | [92.3](/filings/0000950170-25-104822.md) | [93.8](/filings/0001193125-25-268881.md) | [98.5](/filings/0001193125-25-268881.md) | [98.6](/filings/0001193125-26-337583.md) | [101](/filings/0001193125-26-337583.md) | [102](/filings/0001193125-26-337583.md) | [104](/filings/0001193125-25-268881.md) | [106](/filings/0001193125-26-337583.md) | [105](/filings/0001193125-26-337583.md) | [104](/filings/0001193125-26-337583.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [4,000 d](/filings/0000950170-24-123874.md) | [2,060 d](/filings/0000950170-25-039251.md) | [825](/filings/0000950170-25-066717.md) | [2,547 d](/filings/0000950170-25-104822.md) | [1,940 d](/filings/0001193125-25-268881.md) | [2,449 d](/filings/0001193125-26-103635.md) | [1,755](/filings/0001193125-26-211192.md) | [3,898 d](/filings/0001193125-26-337583.md) | [4,227 d](/filings/0001193125-25-268881.md) | [2,445 d](/filings/0001193125-26-103635.md) | [4,103](/filings/0001193125-26-211192.md) | [697 d](/filings/0001193125-26-337583.md) |
| Capital expenditure | $k | [737 d](/filings/0000950170-24-123874.md) | [485 d](/filings/0000950170-25-039251.md) | [967](/filings/0000950170-25-066717.md) | [199 d](/filings/0000950170-25-104822.md) | [664 d](/filings/0001193125-25-268881.md) | [270 d](/filings/0001193125-26-103635.md) | [70.0](/filings/0001193125-26-211192.md) | [2,251 d](/filings/0001193125-26-337583.md) | [624 d](/filings/0001193125-25-268881.md) | [296 d](/filings/0001193125-26-103635.md) | [474](/filings/0001193125-26-211192.md) | [1,341 d](/filings/0001193125-26-337583.md) |
| Dividends paid | $k | [294 d](/filings/0000950170-24-123874.md) | [294 d](/filings/0000950170-25-039251.md) | [289](/filings/0000950170-25-066717.md) | [289 d](/filings/0000950170-25-104822.md) | [286 d](/filings/0001193125-25-268881.md) | [400 d](/filings/0001193125-26-103635.md) | [401](/filings/0001193125-26-211192.md) | [403 d](/filings/0001193125-26-337583.md) | [404 d](/filings/0001193125-25-268881.md) | [400 d](/filings/0001193125-26-103635.md) | [395](/filings/0001193125-26-211192.md) | [386 d](/filings/0001193125-26-337583.md) |
| Share repurchases | $k | not reported | not reported | [0.0](/filings/0000950170-25-066717.md) | [817 d](/filings/0000950170-25-104822.md) | [319 d](/filings/0001193125-25-268881.md) | [507 d](/filings/0001193125-26-103635.md) | [535](/filings/0001193125-26-211192.md) | [0.0 d](/filings/0001193125-26-337583.md) | [0.0 d](/filings/0001193125-25-268881.md) | [1,226 d](/filings/0001193125-26-103635.md) | [2,201](/filings/0001193125-26-211192.md) | [1,440 d](/filings/0001193125-26-337583.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [6,371](/filings/0000950170-23-060942.md) | [6,374](/filings/0000950170-24-057688.md) | [6,402](/filings/0000950170-24-094495.md) | [6,404](/filings/0000950170-24-123874.md) | [6,277](/filings/0000950170-25-066717.md) | [6,208](/filings/0000950170-25-104822.md) | [6,157](/filings/0001193125-25-268881.md) | [6,059](/filings/0001193125-26-211192.md) | [6,055](/filings/0001193125-26-337583.md) | [6,068](/filings/0001193125-25-268881.md) | [5,880](/filings/0001193125-26-211192.md) | [5,758](/filings/0001193125-26-337583.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 5,504,709 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-337583.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.